Analysis of 289,000 patients reveals that stopping GLP-1 receptor agonists like semaglutide leads to dramatic weight regain of 60-90% within one year, with complete reversal of cardiometabolic improvements including blood pressure, lipids, and HbA1c normalization within 12-18 months. Early discontinuation under one year particularly increases coronary artery disease and heart failure risks compared to continued therapy.
This comprehensive review fundamentally reframes how we should view these medications—not as temporary interventions but as chronic treatments requiring lifelong commitment, similar to blood pressure or cholesterol medications. The biological reality is stark: orexigenic pathways reactivate and adaptive thermogenesis kicks in once treatment stops, making sustained weight loss nearly impossible without continued pharmaceutical support. For the millions now using these drugs, this evidence suggests treatment discontinuation represents a high-risk clinical transition requiring structured multidisciplinary management rather than simply stopping. The findings challenge the widespread hope that these medications could provide permanent metabolic reset, instead confirming they manage rather than cure metabolic dysfunction.